| 21st Apr 2026 8:57 pm |
MFN |
Egetis Therapeutics: Egetis Therapeutics has successfully carried out a directed share issue amounting to SEK 350 million (approximately USD 38 million) |
| 21st Apr 2026 3:31 pm |
MFN |
Egetis Therapeutics: Egetis Therapeutics announces the intention to carry out a directed share issue of approximately SEK 350 million (approximately USD 38 million) |
| 14th Apr 2026 1:45 pm |
MFN |
Bulletin from Egetis Therapeutics’ Annual General Meeting 2026 |
| 27th Mar 2026 3:42 pm |
MFN |
Egetis Announces FDA Acceptance and Priority Review of NDA for Emcitate® (tiratricol) for MCT8 Deficiency |
| 24th Mar 2026 2:05 pm |
MFN |
Egetis Therapeutics’ Annual Report 2025 published |
| 12th Mar 2026 11:02 am |
RNS |
NOTICE OF ANNUAL GENERAL MEETING IN EGETIS THERAPEUTICS AB (PUBL) |
| 12th Mar 2026 11:02 am |
MFN |
NOTICE OF ANNUAL GENERAL MEETING IN EGETIS THERAPEUTICS AB (PUBL) |
| 26th Feb 2026 6:00 am |
MFN |
Year-End Report January-December 2025 |
| 29th Jan 2026 6:00 am |
MFN |
Egetis Completes the U.S. Rolling NDA Submission for Emcitate® (tiratricol) for Treatment of MCT8 Deficiency |
| 30th Dec 2025 7:00 am |
MFN |
Change in the number of ordinary shares and votes in Egetis Therapeutics |
| 19th Dec 2025 6:00 am |
RNS |
Egetis Therapeutics initiates New Drug Application in the USA for Emcitate® (tiratricol) for MCT8 deficiency |
| 19th Dec 2025 6:00 am |
MFN |
Egetis Therapeutics initiates New Drug Application in the USA for Emcitate® (tiratricol) for MCT8 deficiency |
| 25th Nov 2025 6:00 am |
MFN |
Interim report Q3 2025 |
| 14th Nov 2025 6:00 am |
MFN |
Egetis announces positive results from the ReTRIACt study of Emcitate® (tiratricol) in MCT8 deficiency |
